Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.

about

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.

Item

http://www.wikidata.org/entity/Q41073983

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Atypical Ketoacidosis and Prot ...... gliflozin, an SGLT2 Inhibitor.

@en

type

Item

label

Atypical Ketoacidosis and Prot ...... gliflozin, an SGLT2 Inhibitor.

@en

prefLabel

Atypical Ketoacidosis and Prot ...... gliflozin, an SGLT2 Inhibitor.

@en

P1476

Atypical Ketoacidosis and Prot ...... agliflozin, an SGLT2 Inhibitor

@en

P2093

Masaaki Miyauchi

http://www.w3.org/2001/XMLSchema#string

Masao Toyoda

http://www.w3.org/2001/XMLSchema#string

P2860

Glucagon regulates hepatic kisspeptin to impair insulin secretion

The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Malonyl-CoA: the regulator of fatty acid synthesis and oxidation.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

P304

1673-1678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2169/INTERNALMEDICINE.56.7945

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Masafumi Fukagawa

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28674356

http://www.w3.org/2001/XMLSchema#string

P921

ketoacidosis

P932

5519469

http://www.w3.org/2001/XMLSchema#string